Stock Events

Stock Events

Cel-Sci 

€0
64
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Sep 996
€1,422.75
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

14MayExpected
Q4 2025
Next
-0.58
-0.24
0.09
0.42
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LSR.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap277.02B
Merck & Co. is a leading pharmaceutical company that competes with Cel-Sci in the immunotherapy and cancer treatment space, particularly with their blockbuster cancer drug Keytruda.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb competes in the oncology and immunotherapy sectors, offering products that directly compete with Cel-Sci's Multikine treatment.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is a global pharmaceutical company with a broad portfolio that includes oncology products, competing in the same market as Cel-Sci.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences is involved in the development of immunotherapy treatments for cancer, making it a direct competitor to Cel-Sci.
Novartis
NVS
Mkt Cap279.67B
Novartis AG competes with Cel-Sci in the cancer immunotherapy field, with a strong focus on research and development in this area.
AMGEN
AMGN
Mkt Cap178B
Amgen is a biotechnology company with a focus on cancer treatments and immunotherapies, competing in the same space as Cel-Sci.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG, through its pharmaceuticals division, develops cancer immunotherapies, directly competing with Cel-Sci's product offerings.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca is involved in the development and commercialization of oncology and immunotherapy treatments, making it a competitor to Cel-Sci.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals is known for its innovative treatments in oncology, directly competing with Cel-Sci in the immunotherapy market.
Incyte
INCY
Mkt Cap19.36B
Incyte Corporation focuses on the discovery, development, and commercialization of cancer treatments, including immunotherapies, competing with Cel-Sci.

About

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Show more...
CEO
Mr. Geert R. Kersten Esq.
Employees
43
Country
United States
ISIN
US1508377066

Listings

F
DE
LSR.F
STU
DE
LSR.STU
MU
DE
LSR.MU
BOATS
BOATS
CVM.BOATS

0 Comments

Share your thoughts

FAQ

What is Cel-Sci stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cel-Sci stocks are traded under the ticker LSR.STU.
When is the next Cel-Sci earnings date?▼
Cel-Sci is going to release the next earnings report on May 14, 2026.
What were Cel-Sci earnings last quarter?▼
LSR.STU earnings for the last quarter are -0.58 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
Does Cel-Sci pay dividends?▼
Yes, LSR.STU dividends are paid annual. The last dividend per share was 1,422.75 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Cel-Sci have?▼
As of May 06, 2026, the company has 43 employees.
In which sector is Cel-Sci located?▼
Cel-Sci operates in the Health & Wellness sector.
When did Cel-Sci complete a stock split?▼
The last stock split for Cel-Sci was on May 20, 2025 with a ratio of 1:30.
Where is Cel-Sci headquartered?▼
Cel-Sci is headquartered in Vienna, United States.